anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

220,561-220,620 of 319,975

filter-aware
10
The chart uses a horizontal bar format to represent the development stage of each program.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
11
The diagram is a concentric circle model representing the layers of value in collaborations.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations Beat · Business Model1 hit
12
The slide uses a stepped arrow diagram to show progression from known targets to challenging novel targets.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
13
Includes footnote regarding fixed term bank deposits and currency basis.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
14
Exscientia | Investor Presentation Deck | 76 slidesExscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
15
The slide uses a complex flow diagram combining a linear process with two internal feedback loops (Active Learning).Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
16
The slide uses a circular process flow to represent a proprietary R&D pipeline.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
17
The slide uses a process flow diagram to illustrate a clinical success story.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
18
The slide uses Kaplan-Meier curves to demonstrate clinical efficacy of the platform's drug prioritization.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
19
The slide uses a horizontal process-like layout to showcase four distinct technical pillars.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
20
The slide uses a circular flow diagram to represent the integration of AI and experimental biology.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
21
The diagram illustrates a flywheel-like process of data integration leading to novel targets.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
22
The slide uses a hierarchical clustering heatmap (dendrograms on top and left) to visualize drug sensitivity across 80 small molecules.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
23
The slide illustrates a computational drug discovery workflow using MPO (Multiparameter Optimisation).Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
24
The diagram uses a hub-and-spoke model to show data integration, followed by a funnel for molecule generation and a circular feedback loop for active learning.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
25
The slide features a 3D molecular model and a UI overlay showing various drug discovery metrics like potency, selectivity, and toxicity.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
26
The scatter plot highlights a specific cluster of 'active learning' selections that deviate from the standard Pareto frontier.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
27
The slide uses a small multiples approach to show dose-response curves across multiple patient samples, followed by a summary plot comparing the two groups over time.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
28
Exscientia | Investor Presentation Deck | 76 slidesExscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
29
Exscientia | Investor Presentation Deck | 76 slidesExscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
30
The slide uses a molecular visualization as a background element to emphasize the drug's mechanism of action.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
31
The slide outlines a standard oncology clinical trial design (Phase 1/2) with a transition point at RP2D (Recommended Phase 2 Dose).Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
32
The slide uses a human anatomy diagram to map specific cancer types to their respective organs, totaling approximately 75,000 patients annually.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
33
Includes a biological pathway diagram and a honeycomb diagram for indications.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
34
The slide uses a three-column layout to define technical constraints for drug development.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
35
The table uses a color-coded heatmap to indicate performance against criteria.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
36
The slide presents preclinical efficacy data for a CDK7 inhibitor ('617) in ovarian (OVCAR3) and triple-negative breast cancer (HCC70) models.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
37
The chart is a waterfall plot showing drug response scores across many patient samples, color-coded by diagnosis.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
38
The slide uses a heatmap to correlate '617 sensitivity with synergy outcomes for three different drug combinations.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
39
Venn diagram shows overlap of gene modulation; line charts show dose-response for POLR2A and HNRNPDL.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
40
The slide uses a 3D molecular visualization as a background element.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
41
The slide showcases a successful asset development case study involving AI-driven design.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
42
The slide uses a traffic-light color coding system to highlight the competitive advantage of the company's drug candidate.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
43
The slide uses a process-oriented layout to explain the company's methodology.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
44
The background features a 3D molecular visualization, likely representing the LSD1 protein or the drug binding to it.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
45
Uses MIDD (Model-informed drug development) as a core methodology.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
46
The slide uses a human anatomy diagram to map specific disease indications to their respective patient counts.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
47
Includes a biological pathway diagram showing LSD1 interactions with various complexes and substrates.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
48
Includes a biological pathway diagram and supporting bullet points on therapeutic mechanism and safety profile.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
49
The slide uses a process flow diagram to explain the therapeutic mechanism and competitive advantage of the '539 molecule.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
50
Exscientia | Investor Presentation Deck | 76 slidesExscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
51
The slide uses a three-column layout to define the technical requirements for the drug candidate.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
52
The slide uses a traffic-light color coding system to indicate performance against criteria.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
53
The slide uses a linear process flow to explain a complex drug discovery pipeline.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
54
The chart illustrates a Pareto front in drug discovery, highlighting that the 'best' molecules (on the front) are not always the most information-rich for further development.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
55
The slide uses two distinct chart types (dot plot and line chart with error bars) to demonstrate safety advantages.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
56
Includes box plots for overall differentiation and line plots for patient-specific heterogeneity categorized by differentiation level.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
57
The slide uses a heatmap to visualize synergy (green) vs no synergy (light green) across 6 different drug combinations.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
58
The slide shows two charts: a line chart for tumour volume over time and a dot plot for plasma pro-GRP concentration. Statistical significance markers are present.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
59
Includes a heatmap showing synergy scores across cell lines and two dose-response line charts showing increased inhibition in combination.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
60
The heatmap displays AUC (Response) values across 16 patient samples for three different treatments.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
61
Exscientia | Investor Presentation Deck | 76 slidesExscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
62
MIDD = Model-informed Drug DevelopmentExscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
63
The slide uses a stylized molecular visualization as a background element.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
64
Exscientia | Investor Presentation Deck | 76 slidesExscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
65
Scientific diagram showing the BCR and TLR signaling pathways converging on MALT1 and NF-kB.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
66
The slide uses a three-column layout to define the core pillars of the drug development strategy.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
67
Exscientia | Investor Presentation Deck | 76 slidesExscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
68
The slide uses a heatmap-style table to visualize performance against criteria, with a specific callout box around the UGT1A1 row.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
69
The slide outlines a multi-stage pipeline: Initiate, Analyse, Evolve, 2D Models, 3D Models, and Active Learning.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit